Pfizer

RUXIENCE

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / RUXIENCE – Q5119

Manufacturer:

Pfizer

Name:

RUXIENCE

HCPCS Code Descriptor:

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Category:

Q Code

HCPCS:

Q5119

NDC(s):

00069-0238-01, 00069-0249-01

Primary Type:

Oncology Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

RUXIENCE is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5119 is aligned to the drug RUXIENCE.

Ruxience targets the CD20 protein in red blood cells and is used to treat certain types of cancer and autoimmune disorders. Ruxience is manufactured by Pfizer and is biosimilar to the medication Rituxan (J9311). Ruxience was aligned to the HCPCS code Q5119 in July 2020. Patient assistance programs for this medication can be found through Pfizer enCompass.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/20

HCPCS Effective Date:

7/1/20

HCPCS Short Description:

Inj ruxience, 10 mg

Billing and Coding Guide:

https://www.pfizeroncologytogether.com/files/RUXIENCE_Billing_and_Coding_Guide.pdf

Patient Assistance:

https://www.pfizerencompass.com/